Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $754.00 Price Target at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective dropped by investment analysts at Morgan Stanley from $755.00 to $754.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective suggests a potential upside of 34.70% from the stock's current price.

Other analysts also recently issued research reports about the stock. Bank of America cut their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a research report on Friday, May 30th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Finally, UBS Group cut their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $822.54.

Regeneron Pharmaceuticals Trading Up 1.3%

Shares of REGN traded up $7.18 during midday trading on Thursday, reaching $559.76. The company had a trading volume of 827,335 shares, compared to its average volume of 914,080. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $1,211.20. The stock has a market cap of $60.43 billion, a PE ratio of 14.25, a price-to-earnings-growth ratio of 2.06 and a beta of 0.33. The firm has a 50 day simple moving average of $545.98 and a 200-day simple moving average of $621.52. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $9.55 EPS. Research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Finally, Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.